JP2023547329A5 - - Google Patents

Info

Publication number
JP2023547329A5
JP2023547329A5 JP2023520046A JP2023520046A JP2023547329A5 JP 2023547329 A5 JP2023547329 A5 JP 2023547329A5 JP 2023520046 A JP2023520046 A JP 2023520046A JP 2023520046 A JP2023520046 A JP 2023520046A JP 2023547329 A5 JP2023547329 A5 JP 2023547329A5
Authority
JP
Japan
Prior art keywords
seq
region
sequence
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/077130 external-priority patent/WO2022069724A1/en
Publication of JP2023547329A publication Critical patent/JP2023547329A/ja
Publication of JP2023547329A5 publication Critical patent/JP2023547329A5/ja
Pending legal-status Critical Current

Links

JP2023520046A 2020-10-02 2021-10-01 Ror2へと結合することができる抗体ならびにror2およびcd3に結合する二重特異性抗体 Pending JP2023547329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20199893.7 2020-10-02
EP20199893 2020-10-02
PCT/EP2021/077130 WO2022069724A1 (en) 2020-10-02 2021-10-01 Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3

Publications (2)

Publication Number Publication Date
JP2023547329A JP2023547329A (ja) 2023-11-10
JP2023547329A5 true JP2023547329A5 (https=) 2024-10-08

Family

ID=72744675

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520046A Pending JP2023547329A (ja) 2020-10-02 2021-10-01 Ror2へと結合することができる抗体ならびにror2およびcd3に結合する二重特異性抗体

Country Status (13)

Country Link
US (1) US20230365714A1 (https=)
EP (1) EP4221742A1 (https=)
JP (1) JP2023547329A (https=)
KR (1) KR20230080437A (https=)
CN (1) CN116438198A (https=)
AU (1) AU2021351187A1 (https=)
BR (1) BR112023005742A2 (https=)
CA (1) CA3193914A1 (https=)
CL (1) CL2023000916A1 (https=)
CO (1) CO2023005044A2 (https=)
IL (1) IL301513A (https=)
MX (1) MX2023003749A (https=)
WO (1) WO2022069724A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4642808A2 (en) * 2022-12-30 2025-11-05 The Regents of the University of California Anti-ror-2 antibodies and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US835A (en) 1838-07-12 X i i i x
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
US9615326B2 (en) * 2011-06-30 2017-04-04 Intel Corporation System and method of improving power efficiency in wireless communication system
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US20140322234A1 (en) * 2012-01-03 2014-10-30 The Board Of Trustees Of The Leland Stanford Junior University Analysis and Targeting of ROR2 in Cancer
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
ME03675B (me) 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
CA2945882A1 (en) 2014-04-16 2015-10-22 Ucb Biopharma Sprl Multimeric fc proteins
US11673957B2 (en) * 2015-03-10 2023-06-13 Eureka Therapeutics, Inc. Anti-ROR2 antibodies
IL256562B2 (en) * 2015-07-15 2024-07-01 Genmab As Human CD3 antibodies or chimeras

Similar Documents

Publication Publication Date Title
JP7790754B2 (ja) Cd3を標的とする抗体、二重特異性抗体及びその使用
AU669083B2 (en) Therapeutic compositions comprising recombinant antibodies specific for TNF alpha
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
JP2023517753A5 (https=)
JP2026050358A (ja) 治療用抗cd40リガンド抗体
JP2021517457A5 (https=)
CA3120804A1 (en) Btla antibodies
JP7821159B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
CN112243443A (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
CN119816523A (zh) 抗Nectin-4抗体和包含其的多特异性抗体
JP2023547329A5 (https=)
JP7821161B2 (ja) Bcmaと結合する単一可変ドメイン及び抗原結合分子
JP2022505144A5 (https=)
WO2022095934A1 (zh) 抗Siglec-15抗体及其在制备药物中的应用
WO2013186630A2 (en) Humanized antibodies to ca215
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
JP2025537255A (ja) 抗アルファ5インテグリン抗体及びその使用
JP2025510266A (ja) Cd3を標的とする抗体及びその使用
JP2024517741A (ja) 抗nkg2d抗体及びその使用
US20220387417A1 (en) Pharmaceutical Combination and Use Thereof
WO2024088386A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
WO2024199454A1 (en) Antibodies and variants thereof against human cluster of differentiation 3 protein
CN118745226B (zh) 抗ror1抗体及其应用
RU2808138C1 (ru) Антитело, нацеливающееся на cd3, биспецифическое антитело и их применение